Fingerprint
Dive into the research topics of 'Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
Claus Zachariae, Kenneth Gordon, Alexandra B Kimball, Mark Lebwohl, Andrew Blauvelt, Craig Leonardi, Daniel Braun, Missy McKean-Matthews, Russel Burge, Gregory Cameron